Cephalexin Oral Suspension Recalled for Failed Impurity Specifications
Ascend Laboratories is recalling Cephalexin for Oral Suspension due to failed impurity specifications identified during stability testing. An out-of-specification result for Cephalexin Glucose Adduct was observed at six months.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for a failed impurity specification with no reported illnesses or injuries. The hazard is related to out-of-specification degradation impurities identified during stability testing, which represents a precautionary quality-control issue rather than an active harm event.
Plain-English summary
Ascend Laboratories, LLC is recalling Cephalexin for Oral Suspension, USP, 125 mg per 5 mL, 100 mL bottles (NDC 67877-544-88) distributed nationwide. The recall was initiated after an out-of-specification result was observed in the related substance test during stability analysis at the sixth month. The individual impurity identified was Cephalexin Glucose Adduct.
The affected product includes lot numbers 23141828, 23141829, 23142342, 23142708, 23144035, 23144270, and 24140026, with expiration dates ranging from May 31, 2025, through December 31, 2025. A total of 48,936 bottles were distributed. The product is manufactured by Alkem Laboratories Ltd., India, and distributed by Ascend Laboratories, LLC, Parsippany, NJ.
Patients currently taking this medication should consult their healthcare provider or pharmacist. Do not stop taking the medication without medical guidance.
The recalled product
- Product
- CEPHALEXIN (CEPHALEXIN)
- Brand
- CEPHALEXIN
- Manufacturer
- Ascend Laboratories, LLC
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (13)
- Lot #: 23141828
- 23141829
- Exp Date: 5/31/2025
- 23142342
- Exp Date: 6/30/2025
- 23142708
- Exp Date: 7/31/2025
- 23144035
- Exp Date: 10/31/2025
- 23144270
- Exp Date: 11/302025
- 24140026
- Exp Date: 12/31/2025
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Ascend Laboratories, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · CEPHALEXIN
- ModerateCephalexin Oral Suspension Recalled for Failed Impurities Specifications
FDA (Drugs) · 2025-06-18
- ModerateCephalexin oral suspension recalled for incorrect dose labeling
FDA (Drugs) · 2024-06-12
- LowCephalexin for Oral Suspension Recalled for Back Label Error
FDA (Drugs) · 2024-06-12
- LowCephalexin Oral Suspension Recalled for Incorrect Labeling and Missing Dosage Information
FDA (Drugs) · 2024-06-12
- ModerateCephalexin Oral Suspension Recalled for Incorrect Dosage Label
FDA (Drugs) · 2024-06-12
Same manufacturer · Ascend Laboratories, LLC
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Over Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateFDA Recalls Amlodipine and Olmesartan Tablets Over Failed Dissolution Test
FDA (Drugs) · 2026-07-29
- ModerateDabigatran Etexilate Capsules Recalled Over Impurity Test Failure
FDA (Drugs) · 2026-07-29
Same hazard · impurity specification
See all →- ModerateLorazepam injection vials failed the total related compounds impurity specification
FDA (Drugs) · 2025-08-06
- ModerateTeva pitavastatin tablets recalled after failing impurity and degradation specifications
FDA (Drugs) · 2025-07-09
- ModeratePitavastatin tablets recalled after failing impurity and degradation specifications
FDA (Drugs) · 2025-07-09
- ModerateHealth Mart Fexofenadine Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2022-01-12
- ModerateH.E.B Allergy Relief Fexofenadine Tablets Recalled for Failed Impurity Specifications
FDA (Drugs) · 2022-01-12